Progenics Pharmaceuticals Inc Revenue Growth Rates (PGNX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Progenics Pharmaceuticals Inc  (PGNX)
 

PGNX's Revenue Growth by Quarter and Year

Progenics Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PGNX Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 6.25
FY 6.25

PGNXs Annual Revenue
Progenics Pharmaceuticals Inc's Revenue in the fiscal year 2019 $ 34.99 millions
Progenics Pharmaceuticals Inc's Revenue in the fiscal year 2018 $ 15.62 millions
Progenics Pharmaceuticals Inc's Revenue in the fiscal year 2017 $ 11.70 millions
Progenics Pharmaceuticals Inc's Revenue in the fiscal year 2016 $ 69.43 millions
Progenics Pharmaceuticals Inc's Revenue in the fiscal year 2015 $ 8.68 millions




PGNX Revenue first quarter 2020 Y/Y Growth Comment
Progenics Pharmaceuticals Inc reported Revenue rise of 45.98% year on year in the first quarter 2020, to $ 6.25 millions, this is lower than Progenics Pharmaceuticals Inc's recent average Revenue surge of 406.86%.

Looking into first quarter 2020 results within Major Pharmaceutical Preparations industry 64 other companies have achieved higher Revenue growth. While Progenics Pharmaceuticals Inc' s Revenue jump of 45.98% ranks overall at the positon no. 467 in the first quarter 2020.


PGNX Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - 366.98 % -16.71 % -16.34 %
3rd Quarter September - 5.45 % 97.04 % -94.99 %
2nd Quarter June - 156.96 % 40.07 % -67.33 %
1st Quarter March 45.98 % 34.17 % 35.74 % -4.08 %
FY   - 123.86 % 33.48 % -

Financial Statements
Progenics Pharmaceuticals Inc's first quarter 2020 Revenue $ 6.25 millions PGNX's Income Statement
Progenics Pharmaceuticals Inc's first quarter 2019 Revenue $ 4.28 millions Quarterly PGNX's Income Statement


PGNX Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - 169.7 % -39.1 % 44.07 %
3rd Quarter September - -43.73 % 37.11 % -2.53 %
2nd Quarter June - 132.94 % 21.63 % 17.87 %
1st Quarter March -58.7 % 32.1 % -17.99 % -49.46 %
FY (Year on Year)   - 123.86 % 33.48 % -


Back to PGNX Growth rate Comparisons >> Back to PGNX Growth rate Comparisons >>


Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #65
Healthcare Sector #142
Overall #467

Revenue Y/Y Growth Statistics
High Average Low
4704.61 % 406.86 % -97.55 %
(Sep 30 2016)   (Sep 30 2017)
Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #65
Healthcare Sector #142
Overall #467
Revenue Y/Y Growth Statistics
High Average Low
4704.61 % 406.86 % -97.55 %
(Sep 30 2016)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Progenics Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
695.43 % 82.63 % -99.38 %
(Dec 31 2012)  


PGNX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Progenics Pharmaceuticals Inc disclosed fall in Revenue from the fourth quarter by -58.7% to $ 6.25 millions, from $ 15.13 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2020 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 168 other companies have achieved higher Revenue quarter on quarter growth. While Progenics Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 3765.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #169
Healthcare Sector #538
Overall #3765
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #169
Healthcare Sector #538
Overall #3765
Revenue Q/Q Growth Statistics
High Average Low
695.43 % 82.63 % -99.38 %
(Dec 31 2012)  


PGNX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Progenics Pharmaceuticals Inc disclosed fall in Revenue from the fourth quarter by -58.7% to $ 6.25 millions, from $ 15.13 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2020 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 168 other companies have achieved higher Revenue quarter on quarter growth. While Progenics Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 3765.


Progenics Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)
Cumulative Revenue 12 Months Ending $ 36.95 $ 34.99 $ 23.10 $ 22.80 $ 16.71
Y / Y Revenue Growth (TTM) 121.09 % 123.95 % 41.94 % 67.01 % 33.29 %
Year on Year Revenue Growth Overall Ranking # 175 # 125 # 183 # 280 # 352
Seqeuential Revenue Change (TTM) 5.62 % 51.47 % 1.3 % 36.42 % 6.99 %
Seq. Revenue Growth (TTM) Overall Ranking # 676 # 168 # 954 # 118 # 520


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2020 period, Progenics Pharmaceuticals Inc's cumulative twelve months Revenue were $ 37 millions, company would post below average annual Revenue growth of 6.99% year on year, if the fiscal year would end at Mar 31 2020.
A slow-down in the Progenics Pharmaceuticals Inc's Revenue growth from the 15.13% growth in Dec 31 2019.

In the Healthcare sector 50 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 125 to 175.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 51
Overall # 175

Revenue TTM Y/Y Growth Statistics
High Average Low
700.24 %
 130.99 %
-83.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 172
S&P 500 # 676
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2020 period, Progenics Pharmaceuticals Inc's cumulative twelve months Revenue were $ 37 millions, company would post below average annual Revenue growth of -83.15% year on year, if the fiscal year would end at Mar 31 2020.
A slow-down in the Progenics Pharmaceuticals Inc's Revenue growth from the 15.13% growth in Dec 31 2019.

In the Healthcare sector 50 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 125 to 175.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 51
Overall # 175

Revenue TTM Y/Y Growth Statistics
High Average Low
700.24 %
130.99 %
-83.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 172
S&P 500 # 676




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PGNX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2020
Genmark Diagnostics Inc 79.92%$ 79.919 millions
Nektar Therapeutics79.20%$ 79.197 millions
Electrocore Inc 79.14%$ 79.143 millions
Amicus Therapeutics inc 77.77%$ 77.774 millions
Vertex Pharmaceuticals Inc76.50%$ 76.496 millions
Stemline Therapeutics Inc75.74%$ 75.745 millions
La Jolla Pharmaceutical Company72.72%$ 72.719 millions
Progyny Inc 71.67%$ 71.672 millions
Inotiv Inc 71.36%$ 71.361 millions
Neurocrine Biosciences Inc 71.31%$ 71.311 millions
Precision Optics Corporation Inc 71.27%$ 71.270 millions
Precipio inc 70.55%$ 70.547 millions
Insmed Inc68.30%$ 68.295 millions
Cytomx Therapeutics Inc 68.20%$ 68.197 millions
Northwest Biotherapeutics Inc68.14%$ 68.142 millions
Cytosorbents Corporation67.72%$ 67.718 millions
Notable Labs Ltd 67.12%$ 67.123 millions
Zynex inc 65.59%$ 65.594 millions
Hookipa Pharma inc 65.37%$ 65.369 millions
Adaptive Biotechnologies Corporation65.09%$ 65.088 millions
Sangamo Therapeutics Inc 62.01%$ 62.012 millions
Scholar Rock Holding Corp61.94%$ 61.945 millions
Transmedics Group Inc 61.04%$ 61.035 millions
Adapthealth Corp 60.20%$ 60.202 millions
Lifemd Inc 59.50%$ 59.497 millions
Invitae Corporation58.43%$ 58.430 millions
Optinose Inc 57.77%$ 57.775 millions
Tivity Health Inc 57.71%$ 57.713 millions
Five Prime Therapeutics Inc 57.36%$ 57.359 millions
Acceleron Pharma inc56.26%$ 56.259 millions


About Progenics Pharmaceuticals Inc Revenue Growth Rates (PGNX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.